Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471767 · ClinicalTrials.gov registry record · Phase 2
AXS-05 Phase II Trial on Smoking Behavior
A Phase 2 study of Smoking Cessation and Nicotine Dependence, sponsored by James Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT03471767: Completed Phase 2 study of Smoking Cessation and Nicotine Dependence, sponsored by James Davis.
NCT03471767 is a Phase 2 study of Smoking Cessation and Nicotine Dependence that has completed, run by James Davis. The registered enrollment target is 58 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471767, a Phase 2 study of Smoking Cessation and Nicotine Dependence, has completed, sponsored by James Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.
Primary Outcome
Smoking intensity refers to the number of cigarettes smoked per day.
Conditions Studied
Interventions
- DRUG AXS-05
- DRUG Bupropion SR
Study Locations (1)
North Carolina
- Duke Center for Smoking Cessation - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-03-25 |
| Est. Completion | 2019-03-31 |
| Phase | Phase 2 |
What the finished NCT03471767 record still lists
NCT03471767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which AXS-05 is the first listed.
NCT03471767 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03471767 about?
NCT03471767 is a clinical study titled "AXS-05 Phase II Trial on Smoking Behavior". This research study is designed with the purpose of evaluating a new drug, combination Dextromethorphan-Bupropion (AXS-05), for its effects on smoking behavior.
What is the current status of trial NCT03471767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2018-03-25. Estimated completion is 2019-03-31.
What conditions does trial NCT03471767 study?
This clinical trial studies the following conditions: Smoking Cessation, Nicotine Dependence, Smoking, Cigarette.
What interventions are being tested in trial NCT03471767?
The interventions under investigation include: AXS-05 (DRUG), Bupropion SR (DRUG).
Who is sponsoring clinical trial NCT03471767?
This trial is sponsored by James Davis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03471767 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03471767's enrollment target sits among peer trials
58 139th of 188 higher than 50 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI